ClinicalTrials.gg
CompletedNCT02395133SOLO-CONTINUEUpdated Mar 11, 2020Results posted

A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD)

A Phase 3 interventional study of Dupilumab and Placebo in Atopic Dermatitis, sponsored by Regeneron Pharmaceuticals. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-11.

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
422
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 50 studies testing dupilumab in Dermatitis, Atopic — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Dermatitis, Atopic.

Enrollment
7th of 50
422 · median 75
Started
2015
with 3 others
Phase 3
11 of 50
none open now
Registered
11th of 50
by date
Lead sponsor
22 of 50
Regeneron Pharmaceuticals

Among the 50 studies testing dupilumab in Dermatitis, Atopic, this one is the 7th largest by enrollment, is one of 4 that started in 2015, is one of 11 in phase 3, and was the 11th registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 50 studies testing dupilumab in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing dupilumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The primary objective of the study was to assess the ability of different Dupilumab dose regimens, administered as monotherapy, to maintain the treatment response achieved after 16 weeks of initial treatment with Dupilumab monotherapy compared to placebo.

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • Eczema
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Must have completed the treatment phase in 1 of the two 16-week initial treatment studies (R668-AD-1334 or R668-AD-1416).
  2. Must have achieved at least 1 of the following 2 treatment success criteria:

    Investigator Global Assessment (IGA) = 0 or 1 (clear or almost clear) at week 16 OR Eczema Area and Severity Index >= 75% (EASI-75) (at least 75% reduction in EASI score from baseline to week 16)

  3. Must be willing and able to comply with clinic visits and study-related procedures
  4. Must provide signed
  5. Must be able to understand and complete study-related questionnaires

Key Exclusion Criteria:

  1. Receipt of rescue medication for AD in the initial treatment study
  2. Any conditions that require permanent discontinuation of study treatment in either initial treatment study
  3. Planned or anticipated major surgical procedure during the participants's participation in this study
  4. Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during this study
  5. Women unwilling to use adequate , if of * and sexually active. Adequate birth control is defined as agreement to consistently practice an effective and accepted method of contraception, whenever engaging in heterosexual intercourse, throughout the duration of the study and for 120 days after last dose of study drug. These include hormonal contraceptives, intrauterine device, or double barrier contraception (e.g, condom + diaphragm), or a male partner with documented vasectomy. Additional requirements for acceptable contraception may apply in certain countries, based on local regulations. Investigators in these countries will be notified accordingly in a protocol clarification letter.

(*For females, menopause is defined as at least 12 consecutive months without menses; if in question, a follicle stimulating hormone level of >= 25 milli units per milliliter (mU/mL) must be documented. Hysterectomy, bilateral oophorectomy, or bilateral tubal ligation must be documented, as applicable; if documented, women with these conditions are not required to use additional contraception).

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
422 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Subcutaneous injection of Placebo (for Dupilumab) was administered once weekly (QW) from Week 1 (Day 1) to Week 36.

    Drug: Placebo

  • Experimental
    Dupilumab 300 mg Q8W

    Subcutaneous injection of Dupilumab 300 milligram (mg) alternatively with placebo (matched to Dupilumab) was administered once every eight week (Q8W) from Week 1 to Week 36.

    Drug: Dupilumab

  • Experimental
    Dupilumab 300 mg Q4W

    Subcutaneous injection of Dupilumab 300 mg alternatively with placebo (matched to Dupilumab) was administered once every four week (Q4W) from Week 1 to Week 36.

    Drug: Dupilumab

  • Experimental
    Dupilumab 300 mg Q2W/QW

    Subcutaneous injection of Dupilumab 300 mg alternatively with placebo (matched to Dupilumab) was administered once every week (QW) or twice a week (Q2W) from Week 1 to Week 36.

    Drug: Dupilumab

Interventions

  • Subcutaneous injection of Dupilumab 300 mg alternatively with placebo (matched to Dupilumab) was administered.

    Also known as: REGN668, SAR231893

  • DrugPlacebo

    Subcutaneous injection of Placebo (for Dupilumab) was administered once weekly (QW).

06

What researchers measure

Primary outcomes

  1. Difference Between Current Study Baseline and Week 36 in Percent Change in EASI From Parent Study Baseline (NCT02277743 and NCT02277769)

    The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Difference of percent change in EASI between current study baseline and week 36 in from parent study baseline (NCT02277743 and NCT02277769) was reported. Values after first rescue treatment used were set to missing before multiple imputation (MI).

    Time frame: Baseline (Parent Study), Baseline (Current Study) and Week 36 (Current study)

  2. Percentage of Participants With Eczema Area and Severity Index >= 75% [EASI-75] at Baseline of Current Study Maintaining EASI-75 at Week 36

    The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-75 responders were the participants who achieved \>=75% overall improvement in EASI score at Week 36. Values after first rescue treatment used were set to missing. Patients with missing value at week 36 were considered as a non-responder.

    Time frame: Week 36

Secondary outcomes

  1. Percentage of Participants Maintaining Investigator Global Assessment (IGA) Response Within 1 Point of Baseline at Week 36

    IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). Participants with IGA score of 0 or 1 at baseline and maintaining within 1 point of baseline were reported as responders. Values after first rescue treatment used were set to missing. Participants with missing value at a visit were considered as a non-responder.

    Time frame: Baseline, Week 36

  2. Percentage of Participants Maintaining Investigator Global Assessment (IGA) Response at 0 or 1 Point at Week 36

    IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). Participants with IGA score of 0 or 1 at week 36 were reported as responders. Values after first rescue treatment were set to missing and participants with missing IGA scores at Week 36 were considered as non-responders.

    Time frame: Week 36

  3. Percentage of Participants With Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score Increased by 3 or More Points From Baseline to Week 35

    Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Values after first rescue treatment were set to missing and participants with missing peak NRS at Week 35 were considered as non-responders.

    Time frame: Baseline up to Week 35

  4. Time to First Event of Investigator's Global Assessment (IGA) >= 2 for Participants With IGA 0 or 1 at Baseline

    IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear).

    Time frame: Baseline up to Week 36

  5. Percentage of Participants With Increased Investigator's Global Assessment (IGA) Score 3 or 4 at Week 36

    IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). Values after first rescue treatment were set to missing and participants with missing IGA scores at Week 36 were considered as responders (i.e. having a increase 3 or 4 of IGA value).

    Time frame: Week 36

  6. Percentage of Participants With Eczema Area and Severity Index-50 (EASI-50) (>= 50% Reduction in EASI Score) at Week 36

    The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-50 responders were the participants who achieved \>= 50% overall improvement in EASI score from baseline to Week 36. Values after first rescue treatment were set to missing and participants with missing EASI-50 scores at Week 36 were considered as non-responders.

    Time frame: Week 36

  7. Absolute Change From Baseline in Eczema Area and Severity Index (EASI) at Week 36

    The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Values after first rescue treatment were set to missing and participants with missing Values at Week 36 were imputed by using multiple imputation method.

    Time frame: Baseline, Week 36

  8. Absolute Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Week 36

    SCORAD is a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). Values after first rescue treatment used were set to missing (censoring) before MI.

    Time frame: Baseline, Week 36

  9. Absolute Change From Baseline in Peak Daily Pruritus Numerical Rating Scale (NRS) Score at Week 35

    Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Values after first rescue treatment used were set to missing before MI.

    Time frame: Baseline, Week 35

  10. Absolute Change From Baseline in Body Surface Area (BSA) Through Week 36

    BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]). It was reported as a percentage of all major body sections combined. Values after first rescue treatment used were set to missing (censoring) before MI.

    Time frame: Baseline through Week 36

  11. Absolute Change From Baseline Through in Patient Oriented Eczema Measure (POEM) Through Week 36

    The POEM is a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life \[QOL\]). Values after first rescue treatment used were set to missing (censoring) before MI.

    Time frame: Baseline through Week 36

  12. Absolute Change From Baseline in Dermatology Life Quality Index (DLQI) Through Week 36

    The DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on quality of life (QOL). The 10 questions assessed QOL over the past week, with an overall scoring of 0 (absent disease) to 30 (severe disease); a high score was indicative of a poor QOL. Values after first rescue treatment used were set to missing before MI.

    Time frame: Baseline through Week 36

  13. Absolute Change From Baseline in Hospital Anxiety Depression Scale (HADS) Through Week 36

    HADS is a fourteen item scale. Seven of the items relate to anxiety and seven items relate to depression. Each item on the questionnaire is scored from 0 (minimum score) - 3 (maximum score) and this means that a person can score between 0 (no symptoms) and 21 (severe symptoms) for either anxiety or depression. Cut-offs for identifying psychiatric distress has been reported as 7 to 8 for possible presence, 10 to 11 for probable presence, and 14 to 15 for severe anxiety or depression. Values after first rescue treatment used were set to missing before MI.

    Time frame: Baseline through Week 36

  14. Difference Between Current Study Baseline and Week 36 in Percent Change in SCORAD From Parent Study Baseline

    SCORAD is a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). Values after first rescue treatment used were set to missing before MI.

    Time frame: Baseline (Parent Study), Baseline (Current Study) and Week 36 (Current study)

  15. Difference Between Current Study Baseline and Week 35 in Percent Change in Peak Weekly Pruritus NRS From Parent Study Baseline

    Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Values after first rescue treatment used were set to missing before MI.

    Time frame: Baseline (Parent Study), Baseline (Current Study) and Week 35 (Current study)

  16. Annualized Event Rate of Skin Infection Treatment- Emergent Adverse Events (TEAEs)

    Any untoward medical occurrence in a participant who received investigational medicinal product (IMP) was considered an AE without regard to possibility of causal relationship with this treatment. Treatment- emergent adverse events (TEAEs) were defined as AEs that developed or worsened or became serious during on- treatment period (time from the first dose of study drug up to the end of study \[Week 36\]). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life- threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs.

    Time frame: Baseline through Week 36

  17. Annualized Event Rate of Flares

    Rate of Flares defined as worsening of disease requiring initiation or escalation of rescue treatment.

    Time frame: Baseline through week 36

  18. Percentage of Well-Controlled Weeks During the On-treatment Period

    Well-controlled weeks are those in which participants during their weekly IVRS call completion has their eczema been well-controlled over the last week during which no rescue treatments were administered. Percentage of well-controlled weeks during the on-treatment period were reported.

    Time frame: Baseline through Week 36

07

Results

Posted Oct 17, 2018

Participant flow

The study was conducted in 15 countries between 25 March 2015 and 18 October 2016. A total of 422 participants were randomized in the study.

Participant flow — Overall Study
MilestonePlacebo QWDupilumab 300 mg Q8WDupilumab 300 mg Q4WDupilumab 300 mg Q2W/QW
Started838486169
Completed697576155
Not completed1491014
Withdrew: Adverse event4130
Withdrew: Lack of efficacy1011
Withdrew: Protocol violation1103
Withdrew: Lost to follow-up0110
Withdrew: Pregnancy0030
Withdrew: Consent withdrawn with no reason given1302
Withdrew: Consent withdrawn with personal reason0103
Withdrew: Sponsor decision2001
Withdrew: Other than specified above5224

Outcome measures

PrimaryDifference Between Current Study Baseline and Week 36 in Percent Change in EASI From Parent Study Baseline (NCT02277743 and NCT02277769)

The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Difference of percent change in EASI between current study baseline and week 36 in from parent study baseline (NCT02277743 and NCT02277769) was reported. Values after first rescue treatment used were set to missing before multiple imputation (MI).

Time frame:
Baseline (Parent Study), Baseline (Current Study) and Week 36 (Current study)
Reported as:
Least squares mean · percent change
Difference Between Current Study Baseline and Week 36 in Percent Change in EASI From Parent Study Baseline (NCT02277743 and NCT02277769)
percent changePlacebo QWDupilumab 300 mg Q8WDupilumab 300 mg Q4WDupilumab 300 mg Q2W/QW
Difference Between Current Study Baseline and Week 36 in Percent Change in EASI From Parent Study Baseline (NCT02277743 and NCT02277769)21.67 ± 3.1346.84 ± 2.4343.84 ± 2.2830.06 ± 1.736
Statistical analysis
  • Placebo QW vs Dupilumab 300 mg Q8W · ANCOVA · p = = 0.0001 · Percent change difference: -14.83 · 95% CI -22.34 to -7.33Threshold for significance at 0.05 level.
  • Placebo QW vs Dupilumab 300 mg Q4W · ANCOVA · p = < 0.0001 · Percent change difference: -17.83 · 95% CI -25.33 to -10.34Threshold for significance at 0.05 level.
  • Placebo QW vs Dupilumab 300 mg Q2W/QW · ANCOVA · p = <0.0001 · Percent change difference: -21.61 · 95% CI -28.36 to -14.87Threshold for significance at 0.05 level.
PrimaryPercentage of Participants With Eczema Area and Severity Index >= 75% [EASI-75] at Baseline of Current Study Maintaining EASI-75 at Week 36

The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-75 responders were the participants who achieved \>=75% overall improvement in EASI score at Week 36. Values after first rescue treatment used were set to missing. Patients with missing value at week 36 were considered as a non-responder.

Time frame:
Week 36
Reported as:
Number · percentage of participants
Percentage of Participants With Eczema Area and Severity Index >= 75% [EASI-75] at Baseline of Current Study Maintaining EASI-75 at Week 36
percentage of participantsPlacebo QWDupilumab 300 mg Q8WDupilumab 300 mg Q4WDupilumab 300 mg Q2W/QW
Percentage of Participants With Eczema Area and Severity Index >= 75% [EASI-75] at Baseline of Current Study Maintaining EASI-75 at Week 3630.454.958.371.6
Statistical analysis
  • Placebo QW vs Dupilumab 300 mg Q8W · Cochran-Mantel-Haenszel · p = = 0.0040 (Threshold for significance at 0.05 level.) · Percentage difference: 24.5 · 95% CI 9.70 to 39.29
  • Placebo QW vs Dupilumab 300 mg Q4W · Cochran-Mantel-Haenszel · p = = 0.0004 (Threshold for significance at 0.05 level.) · Percentage difference: 28.0 · 95% CI 13.32 to 42.58
  • Placebo QW vs Dupilumab 300 mg Q2W/QW · Cochran-Mantel-Haenszel · p = <0.0001 (Threshold for significance at 0.05 level.) · Percentage difference: 41.2 · 95% CI 28.93 to 53.52
SecondaryPercentage of Participants Maintaining Investigator Global Assessment (IGA) Response Within 1 Point of Baseline at Week 36

IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). Participants with IGA score of 0 or 1 at baseline and maintaining within 1 point of baseline were reported as responders. Values after first rescue treatment used were set to missing. Participants with missing value at a visit were considered as a non-responder.

Time frame:
Baseline, Week 36
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining Investigator Global Assessment (IGA) Response Within 1 Point of Baseline at Week 36
percentage of participantsPlacebo QWDupilumab 300 mg Q8WDupilumab 300 mg Q4WDupilumab 300 mg Q2W/QW
Percentage of Participants Maintaining Investigator Global Assessment (IGA) Response Within 1 Point of Baseline at Week 3628.650.062.170.6
Statistical analysis
  • Placebo QW vs Dupilumab 300 mg Q8W · Cochran-Mantel-Haenszel · p = = 0.0130 (Threshold for significance at 0.05 level.) · Percentage difference: 21.4 · 95% CI 4.86 to 38.00
  • Placebo QW vs Dupilumab 300 mg Q4W · Cochran-Mantel-Haenszel · p = = 0.0003 (Threshold for significance at 0.05 level.) · Percentage difference: 33.5 · 95% CI 17.38 to 49.72
  • Placebo QW vs Dupilumab 300 mg Q2W/QW · Cochran-Mantel-Haenszel · p = <0.0001 (Threshold for significance at 0.05 level.) · Percentage difference: 42.1 · 95% CI 28.36 to 55.76
SecondaryPercentage of Participants Maintaining Investigator Global Assessment (IGA) Response at 0 or 1 Point at Week 36

IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). Participants with IGA score of 0 or 1 at week 36 were reported as responders. Values after first rescue treatment were set to missing and participants with missing IGA scores at Week 36 were considered as non-responders.

Time frame:
Week 36
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining Investigator Global Assessment (IGA) Response at 0 or 1 Point at Week 36
percentage of participantsPlacebo QWDupilumab 300 mg Q8WDupilumab 300 mg Q4WDupilumab 300 mg Q2W/QW
Percentage of Participants Maintaining Investigator Global Assessment (IGA) Response at 0 or 1 Point at Week 3614.332.843.954.0
Statistical analysis
  • Placebo QW vs Dupilumab 300 mg Q8W · Cochran-Mantel-Haenszel · p = = 0.0209 (Threshold for significance at 0.05 level.) · Percentage difference: 18.5 · 95% CI 4.14 to 32.91
  • Placebo QW vs Dupilumab 300 mg Q4W · Cochran-Mantel-Haenszel · p = = 0.0007 (Threshold for significance at 0.05 level.) · Percentage difference: 29.7 · 95% CI 14.89 to 44.42
  • Placebo QW vs Dupilumab 300 mg Q2W/QW · Cochran-Mantel-Haenszel · p = <0.0001 (Threshold for significance at 0.05 level.) · Percentage difference: 39.7 · 95% CI 27.42 to 51.95
SecondaryPercentage of Participants With Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score Increased by 3 or More Points From Baseline to Week 35

Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Values after first rescue treatment were set to missing and participants with missing peak NRS at Week 35 were considered as non-responders.

Time frame:
Baseline up to Week 35
Reported as:
Number · percentage of participants
Percentage of Participants With Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score Increased by 3 or More Points From Baseline to Week 35
percentage of participantsPlacebo QWDupilumab 300 mg Q8WDupilumab 300 mg Q4WDupilumab 300 mg Q2W/QW
Percentage of Participants With Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score Increased by 3 or More Points From Baseline to Week 3570.055.649.433.9
Statistical analysis
  • Placebo QW vs Dupilumab 300 mg Q8W · Cochran-Mantel-Haenszel · p = 0.1048 (Threshold for significance at 0.05 level.) · Percentage difference: -14.4 · 95% CI -29.21 to 0.32
  • Placebo QW vs Dupilumab 300 mg Q4W · Cochran-Mantel-Haenszel · p = = 0.0107 (Threshold for significance at 0.05 level.) · Percentage difference: -20.6 · 95% CI -35.32 to -5.89
  • Placebo QW vs Dupilumab 300 mg Q2W/QW · Cochran-Mantel-Haenszel · p = <0.0001 (Threshold for significance at 0.05 level.) · Percentage difference: -36.1 · 95% CI -48.40 to -23.74
SecondaryTime to First Event of Investigator's Global Assessment (IGA) >= 2 for Participants With IGA 0 or 1 at Baseline

IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear).

Time frame:
Baseline up to Week 36
Reported as:
Median · Days
Time to First Event of Investigator's Global Assessment (IGA) >= 2 for Participants With IGA 0 or 1 at Baseline
DaysPlacebo QWDupilumab 300 mg Q8WDupilumab 300 mg Q4WDupilumab 300 mg Q2W/QW
Time to First Event of Investigator's Global Assessment (IGA) >= 2 for Participants With IGA 0 or 1 at Baseline57 (56 to 58)85 (59 to 113)80 (55 to 85)114 (85 to 169)
SecondaryPercentage of Participants With Increased Investigator's Global Assessment (IGA) Score 3 or 4 at Week 36

IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). Values after first rescue treatment were set to missing and participants with missing IGA scores at Week 36 were considered as responders (i.e. having a increase 3 or 4 of IGA value).

Time frame:
Week 36
Reported as:
Number · percentage of participants
Percentage of Participants With Increased Investigator's Global Assessment (IGA) Score 3 or 4 at Week 36
percentage of participantsPlacebo QWDupilumab 300 mg Q8WDupilumab 300 mg Q4WDupilumab 300 mg Q2W/QW
Percentage of Participants With Increased Investigator's Global Assessment (IGA) Score 3 or 4 at Week 3666.748.434.826.2
SecondaryPercentage of Participants With Eczema Area and Severity Index-50 (EASI-50) (>= 50% Reduction in EASI Score) at Week 36

The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-50 responders were the participants who achieved \>= 50% overall improvement in EASI score from baseline to Week 36. Values after first rescue treatment were set to missing and participants with missing EASI-50 scores at Week 36 were considered as non-responders.

Time frame:
Week 36
Reported as:
Number · percentage of participants
Percentage of Participants With Eczema Area and Severity Index-50 (EASI-50) (>= 50% Reduction in EASI Score) at Week 36
percentage of participantsPlacebo QWDupilumab 300 mg Q8WDupilumab 300 mg Q4WDupilumab 300 mg Q2W/QW
Percentage of Participants With Eczema Area and Severity Index-50 (EASI-50) (>= 50% Reduction in EASI Score) at Week 3639.854.860.573.4
SecondaryAbsolute Change From Baseline in Eczema Area and Severity Index (EASI) at Week 36

The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Values after first rescue treatment were set to missing and participants with missing Values at Week 36 were imputed by using multiple imputation method.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · units on a scale
Absolute Change From Baseline in Eczema Area and Severity Index (EASI) at Week 36
units on a scalePlacebo QWDupilumab 300 mg Q8WDupilumab 300 mg Q4WDupilumab 300 mg Q2W/QW
Absolute Change From Baseline in Eczema Area and Severity Index (EASI) at Week 366.61 ± 0.7991.75 ± 0.7381.37 ± 0.7350.09 ± 0.511
SecondaryAbsolute Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Week 36

SCORAD is a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). Values after first rescue treatment used were set to missing (censoring) before MI.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · units on a scale
Absolute Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Week 36
units on a scalePlacebo QWDupilumab 300 mg Q8WDupilumab 300 mg Q4WDupilumab 300 mg Q2W/QW
Absolute Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Week 3618.61 ± 2.1076.62 ± 2.0102.25 ± 1.8990.99 ± 1.350
SecondaryAbsolute Change From Baseline in Peak Daily Pruritus Numerical Rating Scale (NRS) Score at Week 35

Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Values after first rescue treatment used were set to missing before MI.

Time frame:
Baseline, Week 35
Reported as:
Least squares mean · units on a scale
Absolute Change From Baseline in Peak Daily Pruritus Numerical Rating Scale (NRS) Score at Week 35
units on a scalePlacebo QWDupilumab 300 mg Q8WDupilumab 300 mg Q4WDupilumab 300 mg Q2W/QW
Absolute Change From Baseline in Peak Daily Pruritus Numerical Rating Scale (NRS) Score at Week 352.5 ± 0.291.1 ± 0.270.6 ± 0.25-0.1 ± 0.20
SecondaryAbsolute Change From Baseline in Body Surface Area (BSA) Through Week 36

BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]). It was reported as a percentage of all major body sections combined. Values after first rescue treatment used were set to missing (censoring) before MI.

Time frame:
Baseline through Week 36
Reported as:
Least squares mean · meter square
Absolute Change From Baseline in Body Surface Area (BSA) Through Week 36
meter squarePlacebo QWDupilumab 300 mg Q8WDupilumab 300 mg Q4WDupilumab 300 mg Q2W/QW
Absolute Change From Baseline in Body Surface Area (BSA) Through Week 369.16 ± 1.6422.74 ± 1.5301.74 ± 1.457-1.27 ± 1.044
SecondaryAbsolute Change From Baseline Through in Patient Oriented Eczema Measure (POEM) Through Week 36

The POEM is a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life \[QOL\]). Values after first rescue treatment used were set to missing (censoring) before MI.

Time frame:
Baseline through Week 36
Reported as:
Least squares mean · units on a scale
Absolute Change From Baseline Through in Patient Oriented Eczema Measure (POEM) Through Week 36
units on a scalePlacebo QWDupilumab 300 mg Q8WDupilumab 300 mg Q4WDupilumab 300 mg Q2W/QW
Absolute Change From Baseline Through in Patient Oriented Eczema Measure (POEM) Through Week 367.0 ± 0.902.8 ± 0.780.8 ± 0.73-0.3 ± 0.56
SecondaryAbsolute Change From Baseline in Dermatology Life Quality Index (DLQI) Through Week 36

The DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on quality of life (QOL). The 10 questions assessed QOL over the past week, with an overall scoring of 0 (absent disease) to 30 (severe disease); a high score was indicative of a poor QOL. Values after first rescue treatment used were set to missing before MI.

Time frame:
Baseline through Week 36
Reported as:
Least squares mean · units on a scale
Absolute Change From Baseline in Dermatology Life Quality Index (DLQI) Through Week 36
units on a scalePlacebo QWDupilumab 300 mg Q8WDupilumab 300 mg Q4WDupilumab 300 mg Q2W/QW
Absolute Change From Baseline in Dermatology Life Quality Index (DLQI) Through Week 363.1 ± 0.521.5 ± 0.460.3 ± 0.48-0.2 ± 0.33
SecondaryAbsolute Change From Baseline in Hospital Anxiety Depression Scale (HADS) Through Week 36

HADS is a fourteen item scale. Seven of the items relate to anxiety and seven items relate to depression. Each item on the questionnaire is scored from 0 (minimum score) - 3 (maximum score) and this means that a person can score between 0 (no symptoms) and 21 (severe symptoms) for either anxiety or depression. Cut-offs for identifying psychiatric distress has been reported as 7 to 8 for possible presence, 10 to 11 for probable presence, and 14 to 15 for severe anxiety or depression. Values after first rescue treatment used were set to missing before MI.

Time frame:
Baseline through Week 36
Reported as:
Least squares mean · units on a scale
Absolute Change From Baseline in Hospital Anxiety Depression Scale (HADS) Through Week 36
units on a scalePlacebo QWDupilumab 300 mg Q8WDupilumab 300 mg Q4WDupilumab 300 mg Q2W/QW
Absolute Change From Baseline in Hospital Anxiety Depression Scale (HADS) Through Week 360.8 ± 0.600.7 ± 0.520.2 ± 0.54-0.8 ± 0.39
SecondaryDifference Between Current Study Baseline and Week 36 in Percent Change in SCORAD From Parent Study Baseline

SCORAD is a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). Values after first rescue treatment used were set to missing before MI.

Time frame:
Baseline (Parent Study), Baseline (Current Study) and Week 36 (Current study)
Reported as:
Least squares mean · Percent change
Difference Between Current Study Baseline and Week 36 in Percent Change in SCORAD From Parent Study Baseline
Percent changePlacebo QWDupilumab 300 mg Q8WDupilumab 300 mg Q4WDupilumab 300 mg Q2W/QW
Difference Between Current Study Baseline and Week 36 in Percent Change in SCORAD From Parent Study Baseline28.97 ± 3.68310.42 ± 2.9882.21 ± 2.7430.33 ± 2.092
SecondaryDifference Between Current Study Baseline and Week 35 in Percent Change in Peak Weekly Pruritus NRS From Parent Study Baseline

Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Values after first rescue treatment used were set to missing before MI.

Time frame:
Baseline (Parent Study), Baseline (Current Study) and Week 35 (Current study)
Reported as:
Least squares mean · percent change
Difference Between Current Study Baseline and Week 35 in Percent Change in Peak Weekly Pruritus NRS From Parent Study Baseline
percent changePlacebo QWDupilumab 300 mg Q8WDupilumab 300 mg Q4WDupilumab 300 mg Q2W/QW
Difference Between Current Study Baseline and Week 35 in Percent Change in Peak Weekly Pruritus NRS From Parent Study Baseline35.6 ± 4.3216.7 ± 4.098.6 ± 4.02-0.1 ± 3.05
SecondaryAnnualized Event Rate of Skin Infection Treatment- Emergent Adverse Events (TEAEs)

Any untoward medical occurrence in a participant who received investigational medicinal product (IMP) was considered an AE without regard to possibility of causal relationship with this treatment. Treatment- emergent adverse events (TEAEs) were defined as AEs that developed or worsened or became serious during on- treatment period (time from the first dose of study drug up to the end of study \[Week 36\]). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life- threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs.

Time frame:
Baseline through Week 36
Reported as:
Median · events per year
Annualized Event Rate of Skin Infection Treatment- Emergent Adverse Events (TEAEs)
events per yearPlacebo QWDupilumab 300 mg Q8WDupilumab 300 mg Q4WDupilumab 300 mg Q2W/QW
Annualized Event Rate of Skin Infection Treatment- Emergent Adverse Events (TEAEs)0.12 (0.044 to 0.338)0.07 (0.024 to 0.226)0.02 (0.005 to 0.120)0.02 (0.007 to 0.083)
SecondaryAnnualized Event Rate of Flares

Rate of Flares defined as worsening of disease requiring initiation or escalation of rescue treatment.

Time frame:
Baseline through week 36
Reported as:
Median · events per year
Annualized Event Rate of Flares
events per yearPlacebo QWDupilumab 300 mg Q8WDupilumab 300 mg Q4WDupilumab 300 mg Q2W/QW
Annualized Event Rate of Flares0.75 (0.465 to 1.214)0.60 (0.363 to 0.977)0.39 (0.231 to 0.661)0.24 (0.146 to 0.380)
SecondaryPercentage of Well-Controlled Weeks During the On-treatment Period

Well-controlled weeks are those in which participants during their weekly IVRS call completion has their eczema been well-controlled over the last week during which no rescue treatments were administered. Percentage of well-controlled weeks during the on-treatment period were reported.

Time frame:
Baseline through Week 36
Reported as:
Mean · percentage of weeks
Percentage of Well-Controlled Weeks During the On-treatment Period
percentage of weeksPlacebo QWDupilumab 300 mg Q8WDupilumab 300 mg Q4WDupilumab 300 mg Q2W/QW
Percentage of Well-Controlled Weeks During the On-treatment Period40.9 ± 30.3553.2 ± 32.9552.3 ± 35.9663.6 ± 32.08

Adverse events

Collected over All Adverse Events (AEs) were collected from signature of the informed consent form up to the final visit (Week 36) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo QW0/82 (0%)1/82 (1.2%)55/82 (67.1%)
Dupilumab 300 mg Q8W0/84 (0%)3/84 (3.6%)43/84 (51.2%)
Dupilumab 300 mg Q4W1/87 (1.1%)4/87 (4.6%)47/87 (54%)
Dupilumab 300 mg Q2W/QW0/167 (0%)6/167 (3.6%)72/167 (43.1%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventPlacebo QWDupilumab 300 mg Q8WDupilumab 300 mg Q4WDupilumab 300 mg Q2W/QW
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/822/840/870/167
Dermatitis atopicSkin and subcutaneous tissue disorders1/820/840/870/167
Road traffic accidentInjury, poisoning and procedural complications0/820/840/872/167
Muscle injuryInjury, poisoning and procedural complications0/821/840/870/167
Atrial fibrillationCardiac disorders0/820/841/870/167
Tachycardia induced cardiomyopathyCardiac disorders0/820/841/870/167
Gun shot woundInjury, poisoning and procedural complications0/820/841/870/167
GlioblastomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/820/841/870/167
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/820/841/870/167
Abortion inducedSurgical and medical procedures0/820/841/870/167
Most frequent other events
Most frequent other events
EventPlacebo QWDupilumab 300 mg Q8WDupilumab 300 mg Q4WDupilumab 300 mg Q2W/QW
Dermatitis atopicSkin and subcutaneous tissue disorders40/8227/8430/8734/167
NasopharyngitisInfections and infestations11/8211/8411/8732/167
Upper respiratory tract infectionInfections and infestations6/827/845/8713/167
Injection site reactionGeneral disorders2/823/842/8710/167
Oral herpesInfections and infestations3/825/842/873/167
BronchitisInfections and infestations1/820/845/873/167
InfluenzaInfections and infestations1/820/845/874/167
HeadacheNervous system disorders2/823/845/878/167

Baseline characteristics

The full analysis set (FAS) included all randomized participants.

Age, Continuous
Age, Continuous(years)Placebo QWDupilumab 300 mg Q8WDupilumab 300 mg Q4WDupilumab 300 mg Q2W/QWTotal
Mean38.1 ± 13.6437.3 ± 13.9838.5 ± 16.7638.5 ± 13.9438.2 ± 14.46
Sex: Female, Male
Sex: Female, Male(Participants)Placebo QWDupilumab 300 mg Q8WDupilumab 300 mg Q4WDupilumab 300 mg Q2W/QWTotal
Female32334387195
Male51514382227
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo QWDupilumab 300 mg Q8WDupilumab 300 mg Q4WDupilumab 300 mg Q2W/QWTotal
Hispanic or Latino2311016
Not Hispanic or Latino758185155396
Unknown or Not Reported600410
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo QWDupilumab 300 mg Q8WDupilumab 300 mg Q4WDupilumab 300 mg Q2W/QWTotal
American Indian or Alaska Native00000
Asian1718163182
Native Hawaiian or Other Pacific Islander00000
Black or African American784726
White545664124298
More than one race00000
Unknown or Not Reported522716
Region of Enrollment
Region of Enrollment(Participants)Placebo QWDupilumab 300 mg Q8WDupilumab 300 mg Q4WDupilumab 300 mg Q2W/QWTotal
North America38393877192
Japan1211122358
Europe33343669172
Eczema Area and Severity Index (EASI) Score
Eczema Area and Severity Index (EASI) Score(units on a scale)Placebo QWDupilumab 300 mg Q8WDupilumab 300 mg Q4WDupilumab 300 mg Q2W/QWTotal
Mean2.5 ± 2.312.3 ± 2.332.8 ± 3.312.6 ± 2.922.6 ± 2.78
Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS)
Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS)(units on a scale)Placebo QWDupilumab 300 mg Q8WDupilumab 300 mg Q4WDupilumab 300 mg Q2W/QWTotal
Mean2.8 ± 2.112.7 ± 2.273.1 ± 2.162.8 ± 1.922.8 ± 2.08
Body Surface Area (BSA) Involvement with AD
Body Surface Area (BSA) Involvement with AD(percentage of body surface area)Placebo QWDupilumab 300 mg Q8WDupilumab 300 mg Q4WDupilumab 300 mg Q2W/QWTotal
Mean8.1 ± 8.217.9 ± 9.049.3 ± 10.517.9 ± 9.028.2 ± 9.18

4 further baseline measures are reported on the registry.

08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Worm M, Simpson EL, Thaci D, Bissonnette R, Lacour JP, Beissert S, Kawashima M, Ferrandiz C, Smith CH, Beck LA, Chan KC, Chen Z, Akinlade B, Hultsch T, Staudinger H, Gadkari A, Eckert L, Davis JD, Rajadhyaksha M, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD, Ardeleanu M. Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. 2020 Feb 1;156(2):131-143. doi: 10.1001/jamadermatol.2019.3617. PubMed 31876900 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2015 to primary completion in Jul 2016, 16 months.

Results were first posted in Oct 2018, 2 years 3 months after primary completion.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 16 months is below that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2015
First posted
Mar 20, 2015
StartActual
Mar 25, 2015
Primary completionActual
Jul 2016
CompletionActual
Oct 18, 2016
Results first posted
Oct 17, 2018
Last update
Mar 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02395133
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Mar 20, 2015
Start date
Mar 25, 2015
Primary completion
Jul 2016
Completion
Oct 18, 2016
Results posted
Oct 17, 2018
Last update
Mar 11, 2020

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion